Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the kinase inhibitors market?

In recent times, there’s been a significant growth in the kinase inhibitors market. The market valuation is projected to rise from $62.75 billion in 2024 to $67.57 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.7%. Factors contributing to this growth during the historical period include rising prevalence of cancer, advancements in targeted therapy, mounting healthcare expenditure, endorsement of novel kinase inhibitors, and enhanced uptake of tailor-made medicine.

What will be the kinase inhibitors market size in the future?

Expectations are high for the kinase inhibitors market, with predictions pointing to significant growth in the coming years. By 2029, the market is projected to reach a substantial $89.57 billion, with a compound annual growth rate (CAGR) of 7.3%. This anticipated surge during the forecast period can be credited to several factors, including consistent research and development efforts, the launch of innovative kinase inhibitors, broadening uses beyond the field of oncology, increasing financial backing in biotechnology, and increased understanding of precision medicine. Key trends anticipated during the forecast period encompass the advancement of precision oncology treatments, the creation of combination therapies, an intensified focus on rare and challenging-to-treat cancers, progression in biomarker-fueled drug development, and the escalating utilization of next-generation sequencing technologies.

Get your kinase inhibitors market report here!

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

What main drivers are fueling expansion in the kinase inhibitors market?

An upswing in the occurrence of autoimmune diseases is predicted to accelerate the expansion of the kinase inhibitors market. Autoimmune diseases, which mistakenly cause the immune system to attack and destroy healthy cells, tissues, and organs, comprise a wide myriad of disorders. They have become more prevalent due to modifications in lifestyle and diet, genetic predisposition, environmental contamination, stress, imbalance of microbes, and a rising case of chronic illnesses like diabetes, and obesity. Autoimmune conditions can be managed with therapeutic advantages through kinase inhibitors, as they adjust the immune response, lessen inflammation and ease symptoms such as psoriatic and rheumatoid arthritis. For example, in December 2022, the National Psoriasis Foundation, a non-profit organization in the US that aids individuals with psoriasis and psoriatic arthritis, reported that Psoriasis affected over 8 million people in America and 125 million globally, roughly 2 to 3% of the population. Also, in September 2022, according to the Centers for Disease Control and Prevention, a national public health institution in the U.S., it was found that 28.7 million people of all age groups, constituting 8.7% of the US population, were diagnosed with Diabetes, and 5.7% of the total population with confirmed Diabetes which accounts for 1.6 million people, who are 20 or older were reported to have type 1 diabetes and needed insulin. Therefore, the surge in autoimmune diseases is contributing to the expansion of the kinase inhibitors market.

What key areas define the segmentation of the global kinase inhibitors market?

The kinase inhibitors market covered in this report is segmented –

1) By Type: Tyrosine Kinase Inhibitors, Multikinase Inhibitors, mTOR Kinase Inhibitors, Other Types

2) By Route of Administration: Oral, Parenteral, Other Routes

3) By Application: Oncology, Inflammatory Diseases

4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Tyrosine Kinase Inhibitors: EGFR Inhibitors, HER2 Inhibitors, BCR-ABL Inhibitors, Other Tyrosine Kinase Inhibitors

2) By Multikinase Inhibitors: VEGFR Inhibitors, PDGFR Inhibitors, FGFR Inhibitors, Other Multikinase Inhibitors

3) By MTOR Kinase Inhibitors: Everolimus, Temsirolimus, Other MTOR Kinase Inhibitors

4) By Other Types: JAK Inhibitors, ROCK Inhibitors, CDK Inhibitors, Other Kinase Inhibitors

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15841&type=smp

Who are the dominant players expanding their reach in the kinase inhibitors market?

Major companies operating in the kinase inhibitors market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Endo International Inc., Amneal Pharmaceuticals LLC, Lupin Limited, Exelixis Inc., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hutchison China MediTech Limited, Akorn Incorporated, Ocular Therapeutix Inc., Sierra Oncology Inc

What are the key trends shaping the future of the kinase inhibitors market?

Leading businesses in the kinase inhibitors market are working on the development of selective tyrosine kinase 2 (TYK2) inhibitors to fulfill the unaddressed needs in the therapy of autoimmune and inflammatory disorders. TYK2 inhibitors can aid in cancer treatment by adjusting immune reactions and lessening inflammation, thereby boosting the body’s capability to identify and eradicate cancerous cells and creating a less conducive atmosphere for tumor development. For instance, Bristol-Myers Squibb Company, a pharmaceutical enterprise based in the US, got the approval for Sotyktu (deucravacitinib) from the U.S. Food and Drug Administration (FDA) in September 2022. Sotyktu, an oral TYK2 inhibitor, exhibits potential in treating moderate-to-severe plaque psoriasis in adults who necessitate systemic therapy or phototherapy. The launch of Sotyktu marks a substantial progression in the management of plaque psoriasis, and provides a fresh alternative for patients who may not sufficiently react to current treatment methods.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15841

Which regions are emerging as leaders in the kinase inhibitors market?

Asia-Pacific was the largest region in the kinase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kinase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Janus Kinase (JAK) Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

mTOR Inhibitors Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mtor-inhibitors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: